Evidence-Based Medicine Guidelines
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Ipratropium Bromide Versus Short Acting Beta-2 Agonists for Stable Chronic Obstructive Pulmonary Disease." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451482/all/Ipratropium_bromide_versus_short_acting_beta_2_agonists_for_stable_chronic_obstructive_pulmonary_disease.
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/451482/all/Ipratropium_bromide_versus_short_acting_beta_2_agonists_for_stable_chronic_obstructive_pulmonary_disease. Accessed March 26, 2023.
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/451482/all/Ipratropium_bromide_versus_short_acting_beta_2_agonists_for_stable_chronic_obstructive_pulmonary_disease
Ipratropium Bromide Versus Short Acting Beta-2 Agonists for Stable Chronic Obstructive Pulmonary Disease [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 March 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451482/all/Ipratropium_bromide_versus_short_acting_beta_2_agonists_for_stable_chronic_obstructive_pulmonary_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease
ID - 451482
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451482/all/Ipratropium_bromide_versus_short_acting_beta_2_agonists_for_stable_chronic_obstructive_pulmonary_disease
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
